Amy22 Pyrazolopyrimidine Inhibits Myc/Max Dimerization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-cancer therapies lack effective medications for inhibiting tumor growth, particularly due to the challenges in targeting the Myc/Max dimerization pathway without triggering devastating side effects, and existing compounds like 10058-F4 show poor pharmacokinetics leading to limited in vivo efficacy.
Innovation Solution
Development of compounds with a pyrazolo-[1,5-α]-pyrimidine scaffold, such as Amy22, which inhibits Myc/Max dimerization and can be used in combination with other therapeutic agents like COX-2 inhibitors or antimetabolites to treat cancerous diseases, particularly those susceptible to Myc overexpression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecules are used to inhibit Myc/Max dimerization, then the carcinogenic action of Myc can be inhibited, but the compounds show poor pharmacokinetics and limited in vivo efficacy
Solution Approach 1:
The patent modifies the chemical structure of existing Myc/Max dimerization inhibitors by changing parameters such as molecular weight, lipophilicity, and functional groups to improve pharmacokinetic properties. The series of compounds with formula (I) represents systematic parameter changes to optimize both in vitro activity and in vivo performance, directly addressing the poor pharmacokinetics of previous small molecule inhibitors.
2Object-affected harmful factors
If Myc/Max dimerization is inhibited to treat cancer, then tumor growth can be controlled, but systemic inhibition triggers devastating side effects in tissues with rapid turnover
Solution Approach 1:
The patent employs compounds that exhibit selective inhibition of Myc/Max dimerization in cancer cells versus normal cells. The compounds of formula (I) are designed to achieve local quality by preferentially accumulating in or acting on cancerous tissues, thereby controlling tumor growth while minimizing devastating side effects in normal tissues with rapid turnover through selective targeting.
3Productivity
If existing anti-cancer therapies are used, then treatment can be administered, but they lack effective medications for inhibiting tumor growth due to complicated carcinogenesis pathways
Solution Approach 1:
The patent extracts and targets a specific critical interaction (Myc/Max dimerization) from the complicated carcinogenesis pathways. By focusing on this single essential step that Myc must undergo to activate downstream genes, the invention simplifies the therapeutic approach while maintaining effectiveness against tumor growth, avoiding the need to address all the complexity of carcinogenesis pathways simultaneously.
Data Source
AI summary
The invention relates to new compounds of formula (I) that are useful in medicine, specifically in treating or preventing cancerous diseases in a mammal, to pharmaceutical compositions comprising such compounds, optionally together with other pharmaceutically active compounds, or to pharmaceutical formulations comprising such compounds or pharmaceutical compositions. The invention further relates to methods of making these compounds.